Ioana Alexandra Husar-Sburlan

Ioana Alexandra Husar-Sburlan


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2024 in Life
Verified
Journal Article
Open access
RGRaluca Roxana Grigorescu
Raluca Roxana Grigorescu
IHIoana Alexandra Husar-Sburlan
Ioana Alexandra Husar-Sburlan
CGCristian Gheorghe
Cristian Gheorghe
Pancreatic adenocarcinoma is one of the most lethal types of gastrointestinal cancer despite the latest medical advances. Its incidence has continuously increased in recent years in developed countries. The location of the pancreas can result in the initial symptoms of neoplasia being overlooked, which can lead to a delayed diagnosis and a subsequent reduction in the spectrum of available therapeutic options. The role of modifiable risk factors in pancreatic cancer has been extensively studied in recent years, with smoking and alcohol consumption identified as key contributors. However, the few screening programs that have been developed focus exclusively on genetic factors, without considering the potential impact of modifiable factors on disease occurrence. Thus, fully understanding and detecting the risk factors for pancreatic cancer represents an important step in the prevention and early diagnosis of this type of neoplasia. This review reports the available evidence on different risk factors and identifies the areas that could benefit the most from additional studies.

9 February 2023 in Life
Verified
Journal Article
Open access
PDF file
RGRaluca Roxana Grigorescu
Raluca Roxana Grigorescu
IHIoana Alexandra Husar-Sburlan
Ioana Alexandra Husar-Sburlan
GRGeorgiana Florentina Rosulescu
Georgiana Florentina Rosulescu
ABAnca Bobirca
Anca Bobirca
RCRazvan Claudiu Cerban
Razvan Claudiu Cerban
FMFlorescu Madalina
Florescu Madalina
In recent years, we have faced an increasing incidence of inflammatory bowel disease (IBD), especially among young people, affecting them during their reproductive years. The paucity of data and reduced knowledge regarding the evolution of the disease during pregnancy and the adverse effects of the therapy on the mother and infant increase voluntary childlessness in this group of patients. Depending on the type of IBD, severity and surgical or medical management, this can negatively affect the pregnancy. C-sections and the risk of low-birth-weight babies are higher in women with IBD, independent of active/inactive disease, while preterm birth, stillbirth and miscarriage are associated with disease activity. In the last period, medicinal therapy has evolved, and new molecules have been developed for better control of the lesions, but the effect on pregnancy and breastfeeding is still controversial. We conducted this review by studying the literature and recent research in order to have a better image of the practical management of IBD during pregnancy.

1 September 2023 in Medicina
Verified
Journal Article
Open access
PDF file
Cristian CobilinschiCristian Cobilinschi
Cristian Cobilinschi
ISIoana Cristina Saulescu
Ioana Cristina Saulescu
SCsimona caraiola
simona caraiola
ANAndra Florina Nițu
Andra Florina Nițu
Radu Lucian DumitruRadu Lucian Dumitru
Radu Lucian Dumitru
Daniela Opriş-BelinskiDaniela Opriş-Belinski
Daniela Opriş-Belinski
Hemochromatosis is a genetic disorder characterized by increased iron storage in various organs with progressive multisystemic damage. Despite the reports dating back to 1865, the diagnosis of hemochromatosis poses a challenge to clinicians due to its non-specific symptoms and indolent course causing significant delay in disease recognition. The key organ that is affected by iron overload is the liver, suffering from fibrosis, cirrhosis or hepatocellular carcinoma, complications that can be prevented via early diagnosis and treatment. This review aims to draw attention to the pitfalls in diagnosing hemochromatosis. We present a case with multiorgan complaints, abnormal iron markers and a consistent genetic result. We then examine the relevant literature and discuss hemochromatosis subtypes and liver involvement, including transplant outcome and treatment options. In summary, hemochromatosis remains difficult to diagnose due to its symptom heterogeneity and rarity; thus, further education for practitioners of all disciplines is useful in facilitating its early recognition and management.